{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:54:03Z","timestamp":1794020043291,"version":"4.8.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ejpn-journal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ejpn.2024.06.004","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T16:10:37Z","timestamp":1718640637000},"page":"84-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7117-3517","authenticated-orcid":false,"given":"Doris","family":"Giess","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Erdos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejpn.2024.06.004_bib1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ejpn.2024.06.004_bib2","series-title":"Briefing Document to the Clinical Trial Readiness in Spinal Muscular Atrophy (SMA) SMA Europe","year":"2016"},{"issue":"21","key":"10.1016\/j.ejpn.2024.06.004_bib3","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1093\/hmg\/ddq343","article-title":"A humanized Smn gene containing the SMN2 nucleotide alteration in exon 7 mimics SMN2 splicing and the SMA disease phenotype","volume":"19","author":"Gladman","year":"2010","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.ejpn.2024.06.004_bib4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13023-022-02227-7","article-title":"Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study","volume":"17","author":"Veldhoen","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejpn.2024.06.004_bib5","first-page":"6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Genetics"},{"issue":"3","key":"10.1016\/j.ejpn.2024.06.004_bib6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.gde.2013.03.003","article-title":"How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches","volume":"23","author":"Wirth","year":"2013","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.ejpn.2024.06.004_bib7","series-title":"European Medicines Agenccy (EMA). Evrysdi","year":"2023"},{"key":"10.1016\/j.ejpn.2024.06.004_bib8","series-title":"Nusinersen","year":"2020"},{"key":"10.1016\/j.ejpn.2024.06.004_bib9","series-title":"Nutzenbewertung Risdiplam","year":"2021"},{"key":"10.1016\/j.ejpn.2024.06.004_bib10","series-title":"Onasemnogene Abeparvovec","year":"2021"},{"key":"10.1016\/j.ejpn.2024.06.004_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ejpn.2024.06.004_bib12","author":"Edmonton"},{"key":"10.1016\/j.ejpn.2024.06.004_bib13","series-title":"RoB 2: a Revised Tool for Assessing Risk of Bias in Randomised Trials","author":"Sterne","year":"2019"},{"issue":"5","key":"10.1016\/j.ejpn.2024.06.004_bib14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.ejpn.2024.06.004_bib15","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1007\/s00415-023-11711-4","article-title":"An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy","volume":"270","author":"Bjelica","year":"2023","journal-title":"J. Neurol."},{"issue":"21","key":"10.1016\/j.ejpn.2024.06.004_bib16","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ejpn.2024.06.004_bib17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.nmd.2022.04.003","article-title":"Longer-term follow-up of nusinersen efficacy and safety in adult patients with spinal muscular atrophy types 2 and 3","volume":"32","author":"Fainmesser","year":"2022","journal-title":"Neuromuscul. Disord."},{"issue":"7","key":"10.1016\/j.ejpn.2024.06.004_bib18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2352-4642(21)00100-0","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study","volume":"5","author":"Finkel","year":"2021","journal-title":"The Lancet Child & Adolescent Health"},{"issue":"2","key":"10.1016\/j.ejpn.2024.06.004_bib19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.braindev.2022.10.006","article-title":"Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2","volume":"45","author":"Iwayama","year":"2023","journal-title":"Brain Dev."},{"issue":"1","key":"10.1016\/j.ejpn.2024.06.004_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ppul.25140","article-title":"Nusinersen for spinal muscular atrophy type 1: real-world respiratory experience","volume":"56","author":"Lavie","year":"2021","journal-title":"Pediatr. Pulmonol."},{"issue":"3","key":"10.1016\/j.ejpn.2024.06.004_bib21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/ppul.25795","article-title":"Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients","volume":"57","author":"Lavie","year":"2022","journal-title":"Pediatr. Pulmonol."},{"issue":"6","key":"10.1016\/j.ejpn.2024.06.004_bib22","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ppul.25899","article-title":"Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen","volume":"57","author":"Menard","year":"2022","journal-title":"Pediatr. Pulmonol."},{"issue":"3","key":"10.1016\/j.ejpn.2024.06.004_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5603\/PJNNS.a2021.0020","article-title":"Nusinersen treatment of spinal muscular atrophy type 1 - results of expanded access programme in Poland","volume":"55","author":"Modrzejewska","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"issue":"4","key":"10.1016\/j.ejpn.2024.06.004_bib24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mus.26633","article-title":"Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy","volume":"60","author":"Montes","year":"2019","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.ejpn.2024.06.004_bib25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/acn3.51514","article-title":"Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy","volume":"9","author":"Pane","year":"2022","journal-title":"Annals of Clinical & Translational Neurology"},{"issue":"6","key":"10.1016\/j.ejpn.2024.06.004_bib26","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/ene.15768","article-title":"Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function","volume":"30","author":"Pane","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2024.06.004_bib27","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/acn3.51276","article-title":"Type I SMA \"new natural history\": long-term data in nusinersen-treated patients","volume":"8","author":"Pane","year":"2021","journal-title":"Annals of Clinical & Translational Neurology"},{"issue":"1","key":"10.1016\/j.ejpn.2024.06.004_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/JND-221600","article-title":"Improvements in walking distance during nusinersen treatment - a prospective 3-year SMArtCARE registry study","volume":"10","author":"Pechmann","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"issue":"5","key":"10.1016\/j.ejpn.2024.06.004_bib29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nmd.2022.02.001","article-title":"Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland","volume":"32","author":"Tscherter","year":"2022","journal-title":"Neuromuscul. Disord."},{"issue":"7","key":"10.1016\/j.ejpn.2024.06.004_bib30","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/dmcn.15171","article-title":"Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen","volume":"64","author":"Weststrate","year":"2022","journal-title":"Dev. Med. Child Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2024.06.004_bib31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ejpn.2024.06.004_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort","volume":"6","author":"Al-Zaidy","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ejpn.2024.06.004_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy","volume":"98","author":"Lowes","year":"2019","journal-title":"Pediatr. Neurol."},{"issue":"4","key":"10.1016\/j.ejpn.2024.06.004_bib34","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3233\/JND-221531","article-title":"Patients with spinal muscular atrophy type 1 achieve and maintain bulbar function following onasemnogene abeparvovec treatment","volume":"10","author":"McGrattan","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"issue":"5","key":"10.1016\/j.ejpn.2024.06.004_bib35","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpn.2024.06.004_bib36","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2024.06.004_bib37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.ejpn.2024.06.004_bib38","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","article-title":"Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","volume":"270","author":"Oskoui","year":"2023","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.ejpn.2024.06.004_bib39","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-Year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2024.06.004_bib40","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s13023-022-02547-8","article-title":"Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study","volume":"17","author":"Pechmann","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ejpn.2024.06.004_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpeds.2012.05.067","article-title":"Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy","volume":"162","author":"Farrar","year":"2013","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.ejpn.2024.06.004_bib42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40120-023-00444-1","article-title":"Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study","volume":"12","author":"Chiriboga","year":"2023","journal-title":"Neurology and Therapy"},{"issue":"5","key":"10.1016\/j.ejpn.2024.06.004_bib43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mus.27804","article-title":"Risdiplam in non-sitter patients aged 16 years and older with 5q spinal muscular atrophy","volume":"67","author":"Nungo","year":"2023","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.ejpn.2024.06.004_bib44","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13643-016-0226-4","article-title":"Blinding in randomized controlled trials in general and abdominal surgery: protocol for a systematic review and empirical study","volume":"5","author":"Probst","year":"2016","journal-title":"Syst. Rev."},{"issue":"7","key":"10.1016\/j.ejpn.2024.06.004_bib46","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejpn.2024.06.004_bib47","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ppul.25135","article-title":"The respiratory impact of novel therapies for spinal muscular atrophy","volume":"56","author":"Paul","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ejpn.2024.06.004_bib48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejpn.2022.07.005","article-title":"Survival in patients diagnosed with SMA at less than 24 months of age in a population-based setting before, during and after introduction of nusinersen therapy. Experience from Sweden","volume":"40","author":"Berglund","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ejpn.2024.06.004_bib49","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul. Disord."},{"issue":"8","key":"10.1016\/j.ejpn.2024.06.004_bib50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/children9081207","article-title":"Changes in ventilatory support requirements of spinal muscular atrophy (SMA) patients post gene-based therapies","volume":"9","author":"Panagiotou","year":"2022","journal-title":"Children"},{"issue":"1","key":"10.1016\/j.ejpn.2024.06.004_bib51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-020-01667-3","article-title":"Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment","volume":"16","author":"Monnette","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"5","key":"10.1016\/j.ejpn.2024.06.004_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/children10050892","article-title":"Clinical and functional characteristics of a new phenotype of SMA type I among a national sample of Spanish children: a cross-sectional study","volume":"10","author":"de Andr\u00e9s Beltr\u00e1n","year":"2023","journal-title":"Children"},{"key":"10.1016\/j.ejpn.2024.06.004_bib53","doi-asserted-by":"crossref","first-page":"101036","DOI":"10.1016\/j.spen.2023.101036","article-title":"The white coat cape: an ethical analysis of emerging therapies to treat spinal muscular atrophy","volume":"45","author":"Hartsock","year":"2023","journal-title":"Semin. Pediatr. Neurol."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824000904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824000904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T04:58:16Z","timestamp":1721883496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379824000904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":52,"alternative-id":["S1090379824000904"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.06.004","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}